Clinical Profile and Treatment Adherence in Patients with Type 2 Diabetes and Chronic Kidney Disease Who Initiate an SGLT2 Inhibitor: A Multi-cohort Study

Catherine B Johannes; Ryan Ziemiecki; Manel Pladevall-Vila; Natalie Ebert; Csaba P Kovesdy; Reimar W Thomsen; Brenda N Baak; Aníbal García-Sempere; Hiroshi Kanegae; Craig I Coleman; Michael Walsh; Ina Trolle Andersen; Clara Rodríguez Bernal; Celia Robles Cabaniñas; Christian Fynbo Christiansen; Alfredo E Farjat; Alain Gay; Patrick Gee; Ron M C Herings; Isabel Hurtado; Naoki Kashihara; Frederik Pagh Bredahl Kristensen; Fangfang Liu; Suguru Okami; Jetty A Overbeek; Fernie J A Penning-van Beest; Satoshi Yamashita; Yuichiro Yano; J Bradley Layton; David Vizcaya; Nikolaus G Oberprieler

doi:10.1007/s13300-024-01671-x

Clinical Profile and Treatment Adherence in Patients with Type 2 Diabetes and Chronic Kidney Disease Who Initiate an SGLT2 Inhibitor: A Multi-cohort Study

Catherine B Johannes, Ryan Ziemiecki, Manel Pladevall-Vila, Natalie Ebert, Csaba P Kovesdy, Reimar W Thomsen, Brenda N Baak, Aníbal García-Sempere, Hiroshi Kanegae, Craig I Coleman, Michael Walsh, Ina Trolle Andersen, Clara Rodríguez Bernal, Celia Robles Cabaniñas, Christian Fynbo Christiansen, Alfredo E Farjat, Alain Gay, Patrick Gee, Ron M C Herings, Isabel HurtadoNaoki Kashihara, Frederik Pagh Bredahl Kristensen, Fangfang Liu, Suguru Okami, Jetty A Overbeek, Fernie J A Penning-van Beest, Satoshi Yamashita, Yuichiro Yano, J Bradley Layton, David Vizcaya, Nikolaus G Oberprieler^*

^*Corresponding author for this work

Department of Clinical Medicine - Department of Clinical Epidemiology

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

Abstract

INTRODUCTION: The clinical landscape for the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) is rapidly evolving. As part of the FOUNTAIN platform (NCT05526157; EUPAS48148), we described and compared cohorts of adult patients with CKD and T2D initiating a sodium-glucose cotransporter 2 inhibitor (SGLT2i) before the launch of finerenone in Europe, Japan, and the United States (US).

METHODS: This was a multinational, multi-cohort study of patients with T2D in five data sources: the Danish National Health Registers (DNHR) (Denmark), PHARMO Data Network (The Netherlands), Valencia Health System Integrated Database (VID) (Spain), Japan Chronic Kidney Disease Database Extension (J-CKD-DB-Ex) (Japan), and Optum's de-identified Clinformatics ® Data Mart Database (CDM) (US). Eligible patients had CKD (based on either diagnosis codes, eGFR values, and/or urine ACR) and initiated an SGLT2i between 2012 and 2021. Baseline demographic, lifestyle, and clinical characteristics were analyzed, and drug utilization patterns were described.

RESULTS: The final cohorts included 21,739 patients in DNHR, 381 in PHARMO, 31,785 in VID, 1157 in J-CKD-DB-Ex, and 56,219 in CDM. Across data sources, approximately 41-70% had CKD stage 1 or 2 at baseline; severe CKD (stage 4) was uncommon (1.6-6.7%). The median duration of SGLT2i therapy ranged from 7.5 months in PHARMO to 17.0 months in VID. At least 50% of patients were currently receiving SGLT2i treatment at 1 year after initiation.

CONCLUSIONS: At a 1-year follow-up, at least half of the patients with CKD and T2D were receiving SGLT2i treatment across the data sources. In patients initiating SGLT2i, treatment options for T2D and CKD were heterogeneous and dynamic within and among data sources.

Original language	English
Article number	e000154
Journal	Diabetes therapy
Volume	16
Issue	2
Pages (from-to)	205-226
Number of pages	22
ISSN	1869-6953
DOIs	https://doi.org/10.1007/s13300-024-01671-x
Publication status	Published - Feb 2025

Keywords

CKD
Chronic kidney disease
Danish National Health Registers (DNHR)
Drug utilization
FOUNTAIN
Japan Chronic Kidney Disease Database Extension (J-CKD-DB-Ex)
Optum’s de-identified Clinformatics Data Mart Database (CDM)
PHARMO Data Network
SGLT2 inhibitor
T2D
Type 2 diabetes
Valencia Health System Integrated Database (VID)

Access to Document

10.1007/s13300-024-01671-xLicence: CC BY-NC-ND

Library access?

Check availability with the Royal Danish Library

Cite this

Johannes, C. B., Ziemiecki, R., Pladevall-Vila, M., Ebert, N., Kovesdy, C. P., Thomsen, R. W., Baak, B. N., García-Sempere, A., Kanegae, H., Coleman, C. I., Walsh, M., Andersen, I. T., Rodríguez Bernal, C., Robles Cabaniñas, C., Christiansen, C. F., Farjat, A. E., Gay, A., Gee, P., Herings, R. M. C., ... Oberprieler, N. G. (2025). Clinical Profile and Treatment Adherence in Patients with Type 2 Diabetes and Chronic Kidney Disease Who Initiate an SGLT2 Inhibitor: A Multi-cohort Study. Diabetes therapy, 16(2), 205-226. Article e000154. https://doi.org/10.1007/s13300-024-01671-x

@article{5745432f86904b82a1609287c353b9d1,

title = "Clinical Profile and Treatment Adherence in Patients with Type 2 Diabetes and Chronic Kidney Disease Who Initiate an SGLT2 Inhibitor: A Multi-cohort Study",

abstract = "INTRODUCTION: The clinical landscape for the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) is rapidly evolving. As part of the FOUNTAIN platform (NCT05526157; EUPAS48148), we described and compared cohorts of adult patients with CKD and T2D initiating a sodium-glucose cotransporter 2 inhibitor (SGLT2i) before the launch of finerenone in Europe, Japan, and the United States (US).METHODS: This was a multinational, multi-cohort study of patients with T2D in five data sources: the Danish National Health Registers (DNHR) (Denmark), PHARMO Data Network (The Netherlands), Valencia Health System Integrated Database (VID) (Spain), Japan Chronic Kidney Disease Database Extension (J-CKD-DB-Ex) (Japan), and Optum's de-identified Clinformatics {\textregistered} Data Mart Database (CDM) (US). Eligible patients had CKD (based on either diagnosis codes, eGFR values, and/or urine ACR) and initiated an SGLT2i between 2012 and 2021. Baseline demographic, lifestyle, and clinical characteristics were analyzed, and drug utilization patterns were described. RESULTS: The final cohorts included 21,739 patients in DNHR, 381 in PHARMO, 31,785 in VID, 1157 in J-CKD-DB-Ex, and 56,219 in CDM. Across data sources, approximately 41-70% had CKD stage 1 or 2 at baseline; severe CKD (stage 4) was uncommon (1.6-6.7%). The median duration of SGLT2i therapy ranged from 7.5 months in PHARMO to 17.0 months in VID. At least 50% of patients were currently receiving SGLT2i treatment at 1 year after initiation.CONCLUSIONS: At a 1-year follow-up, at least half of the patients with CKD and T2D were receiving SGLT2i treatment across the data sources. In patients initiating SGLT2i, treatment options for T2D and CKD were heterogeneous and dynamic within and among data sources.",

keywords = "CKD, Chronic kidney disease, Danish National Health Registers (DNHR), Drug utilization, FOUNTAIN, Japan Chronic Kidney Disease Database Extension (J-CKD-DB-Ex), Optum{\textquoteright}s de-identified Clinformatics Data Mart Database (CDM), PHARMO Data Network, SGLT2 inhibitor, T2D, Type 2 diabetes, Valencia Health System Integrated Database (VID)",

author = "Johannes, {Catherine B} and Ryan Ziemiecki and Manel Pladevall-Vila and Natalie Ebert and Kovesdy, {Csaba P} and Thomsen, {Reimar W} and Baak, {Brenda N} and An{\'i}bal Garc{\'i}a-Sempere and Hiroshi Kanegae and Coleman, {Craig I} and Michael Walsh and Andersen, {Ina Trolle} and {Rodr{\'i}guez Bernal}, Clara and {Robles Cabani{\~n}as}, Celia and Christiansen, {Christian Fynbo} and Farjat, {Alfredo E} and Alain Gay and Patrick Gee and Herings, {Ron M C} and Isabel Hurtado and Naoki Kashihara and Kristensen, {Frederik Pagh Bredahl} and Fangfang Liu and Suguru Okami and Overbeek, {Jetty A} and {Penning-van Beest}, {Fernie J A} and Satoshi Yamashita and Yuichiro Yano and Layton, {J Bradley} and David Vizcaya and Oberprieler, {Nikolaus G}",

note = "{\textcopyright} 2024. The Author(s).",

year = "2025",

month = feb,

doi = "10.1007/s13300-024-01671-x",

language = "English",

volume = "16",

pages = "205--226",

journal = "Diabetes therapy",

issn = "1869-6953",

publisher = "Springer Publishing Company",

number = "2",

}

Johannes, CB, Ziemiecki, R, Pladevall-Vila, M, Ebert, N, Kovesdy, CP, Thomsen, RW, Baak, BN, García-Sempere, A, Kanegae, H, Coleman, CI, Walsh, M, Andersen, IT, Rodríguez Bernal, C, Robles Cabaniñas, C, Christiansen, CF, Farjat, AE, Gay, A, Gee, P, Herings, RMC, Hurtado, I, Kashihara, N, Kristensen, FPB, Liu, F, Okami, S, Overbeek, JA, Penning-van Beest, FJA, Yamashita, S, Yano, Y, Layton, JB, Vizcaya, D & Oberprieler, NG 2025, 'Clinical Profile and Treatment Adherence in Patients with Type 2 Diabetes and Chronic Kidney Disease Who Initiate an SGLT2 Inhibitor: A Multi-cohort Study', Diabetes therapy, vol. 16, no. 2, e000154, pp. 205-226. https://doi.org/10.1007/s13300-024-01671-x

Clinical Profile and Treatment Adherence in Patients with Type 2 Diabetes and Chronic Kidney Disease Who Initiate an SGLT2 Inhibitor: A Multi-cohort Study. / Johannes, Catherine B; Ziemiecki, Ryan; Pladevall-Vila, Manel et al.
In: Diabetes therapy, Vol. 16, No. 2, e000154, 02.2025, p. 205-226.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

TY - JOUR

T1 - Clinical Profile and Treatment Adherence in Patients with Type 2 Diabetes and Chronic Kidney Disease Who Initiate an SGLT2 Inhibitor

T2 - A Multi-cohort Study

AU - Johannes, Catherine B

AU - Ziemiecki, Ryan

AU - Pladevall-Vila, Manel

AU - Ebert, Natalie

AU - Kovesdy, Csaba P

AU - Thomsen, Reimar W

AU - Baak, Brenda N

AU - García-Sempere, Aníbal

AU - Kanegae, Hiroshi

AU - Coleman, Craig I

AU - Walsh, Michael

AU - Andersen, Ina Trolle

AU - Rodríguez Bernal, Clara

AU - Robles Cabaniñas, Celia

AU - Christiansen, Christian Fynbo

AU - Farjat, Alfredo E

AU - Gay, Alain

AU - Gee, Patrick

AU - Herings, Ron M C

AU - Hurtado, Isabel

AU - Kashihara, Naoki

AU - Kristensen, Frederik Pagh Bredahl

AU - Liu, Fangfang

AU - Okami, Suguru

AU - Overbeek, Jetty A

AU - Penning-van Beest, Fernie J A

AU - Yamashita, Satoshi

AU - Yano, Yuichiro

AU - Layton, J Bradley

AU - Vizcaya, David

AU - Oberprieler, Nikolaus G

PY - 2025/2

Y1 - 2025/2

N2 - INTRODUCTION: The clinical landscape for the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) is rapidly evolving. As part of the FOUNTAIN platform (NCT05526157; EUPAS48148), we described and compared cohorts of adult patients with CKD and T2D initiating a sodium-glucose cotransporter 2 inhibitor (SGLT2i) before the launch of finerenone in Europe, Japan, and the United States (US).METHODS: This was a multinational, multi-cohort study of patients with T2D in five data sources: the Danish National Health Registers (DNHR) (Denmark), PHARMO Data Network (The Netherlands), Valencia Health System Integrated Database (VID) (Spain), Japan Chronic Kidney Disease Database Extension (J-CKD-DB-Ex) (Japan), and Optum's de-identified Clinformatics ® Data Mart Database (CDM) (US). Eligible patients had CKD (based on either diagnosis codes, eGFR values, and/or urine ACR) and initiated an SGLT2i between 2012 and 2021. Baseline demographic, lifestyle, and clinical characteristics were analyzed, and drug utilization patterns were described. RESULTS: The final cohorts included 21,739 patients in DNHR, 381 in PHARMO, 31,785 in VID, 1157 in J-CKD-DB-Ex, and 56,219 in CDM. Across data sources, approximately 41-70% had CKD stage 1 or 2 at baseline; severe CKD (stage 4) was uncommon (1.6-6.7%). The median duration of SGLT2i therapy ranged from 7.5 months in PHARMO to 17.0 months in VID. At least 50% of patients were currently receiving SGLT2i treatment at 1 year after initiation.CONCLUSIONS: At a 1-year follow-up, at least half of the patients with CKD and T2D were receiving SGLT2i treatment across the data sources. In patients initiating SGLT2i, treatment options for T2D and CKD were heterogeneous and dynamic within and among data sources.

AB - INTRODUCTION: The clinical landscape for the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) is rapidly evolving. As part of the FOUNTAIN platform (NCT05526157; EUPAS48148), we described and compared cohorts of adult patients with CKD and T2D initiating a sodium-glucose cotransporter 2 inhibitor (SGLT2i) before the launch of finerenone in Europe, Japan, and the United States (US).METHODS: This was a multinational, multi-cohort study of patients with T2D in five data sources: the Danish National Health Registers (DNHR) (Denmark), PHARMO Data Network (The Netherlands), Valencia Health System Integrated Database (VID) (Spain), Japan Chronic Kidney Disease Database Extension (J-CKD-DB-Ex) (Japan), and Optum's de-identified Clinformatics ® Data Mart Database (CDM) (US). Eligible patients had CKD (based on either diagnosis codes, eGFR values, and/or urine ACR) and initiated an SGLT2i between 2012 and 2021. Baseline demographic, lifestyle, and clinical characteristics were analyzed, and drug utilization patterns were described. RESULTS: The final cohorts included 21,739 patients in DNHR, 381 in PHARMO, 31,785 in VID, 1157 in J-CKD-DB-Ex, and 56,219 in CDM. Across data sources, approximately 41-70% had CKD stage 1 or 2 at baseline; severe CKD (stage 4) was uncommon (1.6-6.7%). The median duration of SGLT2i therapy ranged from 7.5 months in PHARMO to 17.0 months in VID. At least 50% of patients were currently receiving SGLT2i treatment at 1 year after initiation.CONCLUSIONS: At a 1-year follow-up, at least half of the patients with CKD and T2D were receiving SGLT2i treatment across the data sources. In patients initiating SGLT2i, treatment options for T2D and CKD were heterogeneous and dynamic within and among data sources.

KW - CKD

KW - Chronic kidney disease

KW - Danish National Health Registers (DNHR)

KW - Drug utilization

KW - FOUNTAIN

KW - Japan Chronic Kidney Disease Database Extension (J-CKD-DB-Ex)

KW - Optum’s de-identified Clinformatics Data Mart Database (CDM)

KW - PHARMO Data Network

KW - SGLT2 inhibitor

KW - T2D

KW - Type 2 diabetes

KW - Valencia Health System Integrated Database (VID)

UR - http://www.scopus.com/inward/record.url?scp=85212710343&partnerID=8YFLogxK

U2 - 10.1007/s13300-024-01671-x

DO - 10.1007/s13300-024-01671-x

M3 - Journal article

C2 - 39688776

SN - 1869-6953

VL - 16

SP - 205

EP - 226

JO - Diabetes therapy

JF - Diabetes therapy

IS - 2

M1 - e000154

ER -

Clinical Profile and Treatment Adherence in Patients with Type 2 Diabetes and Chronic Kidney Disease Who Initiate an SGLT2 Inhibitor: A Multi-cohort Study

Abstract

Keywords

Access to Document

Library access?

Other files and links

Fingerprint

Cite this